



Brain+ presents its unique digital CST offerings at two key European dementia conferences in October

- At the 33rd Alzheimer's Europe conference, Brain+ shares insight and initial data from its recent work to validate tailored content for its CST-Therapist Companion v 2.0 product aimed to reduce variability in CST outcomes
- At the annual meeting in INTERDEM, the most important pan-European network of researchers and clinicians disseminating psychosocial interventions in dementia, Brain+ presented its distinctive approach to digital delivery of CST
- Brain+ is gaining recognition among patient groups, clinicians and researches as a key opinion leader on digitally delivered psychosocial, non-pharmaceutical interventions for the treatment of dementia

Copenhagen, Denmark, 16 October, 2023 – Brain+ A/S (Nasdaq First North: BRAINP)

Brain+ is solidifying its position as a key opinion leader in psychosocial, non-pharmacological therapeutic interventions for dementia, and the company has presented its distinctive approach to digital delivery of Cognitive Stimulation Therapy (CST) at two dementia conferences in October.

At the **33rd Alzheimer's Europe conference**, held on 16-18 October 2023 in Helsinki, Finland, Brain+ will present a poster titled "*Using Digital Technology to Standardise and Customise Cognitive Stimulation Therapy*". The Poster shares insight into the methodologies and early data behind the development and validation of content for the company's first product for digital delivery of CST, CST-Therapist Companion. CST-Therapist Companion provides CST activities tailored to different cognitive severities and has potential to support large-scale implementation of CST and reduce variability in outcomes. Alzheimer's Europe is a longtime collaborator of Brain+, having participated in several of the company's innovation projects for the development of digital dementia technologies and products.

At the annual **INTERDEM** business meeting, held on 15-16 October 2023 in connection with the Alzheimer's Europe conference, Brain+ showcased its digital CST product offerings to international clinical experts on dementia, including leading CST experts. INTERDEM is a pan-European network of researchers collaborating in the research and dissemination of early, timely and high-quality psychosocial INTERvention in DEMentia; thus enhancing best practice therapeutic initiatives in clinical practice and improving quality of life of people with dementia and their caregivers. Notably, Brain+ has a unique standing as the sole company represented within the INTERDEM network.

Participation at key opinion leadership meetings in dementia is pivotal for Brain+, Participation at leading dementia conferences is of core value to Brain+, serving a dual purpose: Firstly, it ensures that the company's employees stay at the forefront of the most recent findings and knowledge on dementia pathology and therapy, providing insight to feed into the development of cutting-edge therapeutic solutions, asserting also in-house the company's leadership in the field. Secondly, it supports the establishment of in-house clinicians

as recognized experts and facilitates engaging international connections to build trust with clinicians, academics, and advocacy groups, a crucial factor for the integration of Brain+ products into health systems. On top of strong clinical and health economic evidence and real-life experience and reference, network and trust are crucial factors to facilitate the adoption of Brain+ offered products into clinical dementia practice and care.

Last day of TO2 warrant exercise – Pre-commitments received for almost 50%

Today, Monday 16 October 2023 is the last day for holders of Brain+ TO2 warrants to exercise their warrants and subscribe for new shares in the company at the price of DKK 0.20.

On Thursday, 12 October 2023, Brain+ announced commitments from the company's largest shareholders reaching almost 50% of the total outstanding, including commitments from members of its board and management to both exercise all their warrants and act as guarantors for a total amount of DKK 0.4 million.

Contact Information

CEO and Co-founder: Kim Baden-Kristensen, + 45 31393317 (SMS), kim@brain-plus.com

Mission: Bringing effective digitally-delivered dementia therapies to those in need, serving a million people with dementia, care-givers and clinicians by 2030.